M. Kulyk & Associates’s Novo Nordisk NVO Stock Holding History

M. Kulyk & Associates’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.48M	Sell	93,400 -58,911	-39%	-$2.53M	0.73%	40
2026 Q1	$5.6M	Buy	152,311 +71	+0%	+$3.36K	1.04%	33
2025 Q4	$7.75M	Buy	152,240 +22,231	+17%	+$1.14M	1.48%	25
2025 Q3	$7.21M	Buy	130,009 +52,687	+68%	+$3.08M	1.47%	26
2025 Q2	$5.34M	Buy	77,322 +11,425	+17%	+$777K	1.16%	31
2025 Q1	$4.58M	Buy	65,897 +62,715	+1,971%	+$5.18M	1.05%	37
2024 Q4	$274K	Buy	3,182 +119	+4%	+$12.9K	0.06%	85
2024 Q3	$365K	Sell	3,063 -1,573	-34%	-$210K	0.07%	79
2024 Q2	$662K	Sell	4,636 -900	-16%	-$119K	0.15%	59
2024 Q1	$711K	Sell	5,536 -324	-6%	-$38.6K	0.16%	60
2023 Q4	$606K	Buy	+5,860	New	+$580K	0.14%	65

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

M. Kulyk & Associates's NVO Position: Q2 2026 in Review

M. Kulyk & Associates reduced its Novo Nordisk (NVO) stake by 39% in Q2 2026, selling an estimated $2.53M and leaving 93,400 shares worth $4.48M. The position accounts for 0.73% of the portfolio, ranked #40.

M. Kulyk & Associates first reported a position in NVO in Q4 2023 and has held it in 11 quarters since. The position peaked at $7.75M in Q4 2025. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

M. Kulyk & Associates held 93,400 shares of Novo Nordisk worth $4.48M as of Q2 2026.
M. Kulyk & Associates sold 58,911 Novo Nordisk shares in Q2 2026, an estimated $2.53M.
Novo Nordisk made up 0.73% of M. Kulyk & Associates's portfolio in Q2 2026, its #40 holding.
M. Kulyk & Associates first reported a position in Novo Nordisk in Q4 2023 and has held it in 11 quarters since.
M. Kulyk & Associates's Novo Nordisk position peaked at $7.75M in Q4 2025.
1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on M. Kulyk & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.